Fig. 1. Features of KRAS-targeting inRas37 antibody. (A) Schematics of the structures of inRas37 with integrin-targeting in4 cyclic peptide fused to N-terminal and cytosol-penetrating VL (light chain variable domain), active form of RAS•GTP-specific VH (heavy chain variable domain), and LALAPG mutations in the Fc region. (B) ELISA results showing the selective binding affinity of inRas37 compared to the control antibody inCT37 on His KRASG12D∙GppNHp, an active form of KRAS, and KRASG12D∙GDP, an inactive form of KRAS. Data are presented as the means ± SD (*p<0.05 and ***p<0.001).
© Biomolecules & Therapeutics
